Tradestie Institutional Equity Comparison Engine

RGNX vs INBX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

INBX Overall Edge

INBX Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Inhibrx Biosciences, Inc. Common Stock (INBX) driven by superior Growth & Margin, Momentum & Technical while RGNX counters with relative strength in Valuation, Options & Structure. Fundamentally, RGNX trades at N/M Forward P/E with -120.4% operating margin (-69.2% YoY revenue) versus INBX at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, RGNX sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against INBX sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner RGNX
RGNX N/M vs INBX N/M Fwd P/E
Growth & Margin Winner INBX
Op Margin -120.4% vs 0.0% ยท YoY -69.2% vs -100.0%
Momentum & Technical Winner INBX
1Y -35.8% vs +3.6% ยท 52W Pos 19% vs 20%
Options & Structure Winner RGNX
BREAKDOWN (52nd %ile IV) vs BREAKDOWN (8th %ile IV)
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.47
-2.23% 1D
Market Cap $500.9M
1M Return +7.87%
1Y Return -35.82%
Forward P/E N/M
Unified AI Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0
INBX NASDAQ
Inhibrx Biosciences, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$77.32
-7.18% 1D
Market Cap $1.3B
1M Return -13.93%
1Y Return +3.61%
Forward P/E N/M
Unified AI Score
51.4 / 100 HOLD
Tech 48.0 Fund 55.0 Flow 68.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RGNX -35.82% INBX +3.61% Spread: +39.43 pp (INBX Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period RGNX Revenue INBX Revenue RGNX Op. Margin INBX Op. Margin Margin Edge
FY2018 $220M N/A 40.3% N/A RGNX
FY2019 $40M N/A -422.9% N/A RGNX
FY2020 $150M N/A -77.1% N/A RGNX
FY2021 $470M N/A 34.0% N/A RGNX
FY2022 $110M N/A -233.2% N/A RGNX
FY2023 $90M $0M -297.1% -12178.9% RGNX
FY2024 $80M $0M -280.0% -165724.0% RGNX
FY2025 $170M $0M -94.6% -10386.5% RGNX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RGNX (3) vs INBX (5)
Institutional Metric RGNX INBX Criterion Row Winner
Market Capitalization Scale $500.9M $1.3B Larger Scale INBX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -69.2% -100.0% Higher Growth RGNX
Operating Margin (TTM) Profitability -120.4% 0.0% Higher Margin INBX
Net Profit Margin Profitability -113.9% 0.0% Higher Margin INBX
Return on Equity (ROE) Capital Efficiency -113.2% -1773.6% Higher ROE RGNX
52-Week Range Position Momentum 19% ($5โ€“$16) 20% ($57โ€“$155) Stronger Trend INBX
Beta / 30D Volatility Risk Regime 1.81ฮฒ ยท 76% Vol 2.53ฮฒ ยท 120% Vol Lower Realized Risk RGNX
Unified Institutional Score Composite Signal 45.3 / 100 (HOLD) 51.4 / 100 (HOLD) Higher Composite INBX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RGNX vs INBX Buy Guide
RGNX BREAKDOWN
91d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live RGNX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
INBX BREAKDOWN
134d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live INBX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RGNX nor INBX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.